Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

BEVERLY, MA--(Marketwired - Jan 22, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to report that results of its recently completed phase 2b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)" will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial. Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer, will give the presentation during a session entitled "New Antibacterial Agents - Phase 2 and Phase 3 Clinical Trials."

"We worked with the FDA in designing the recent phase 2b study," said Dr. Jorgensen. "As predicted, a lower total dose of Brilacidin, given as a single-dose regimen, was well tolerated and efficacy was comparable to that of the 7-day regimen of the active control, daptomycin."

"It's important to note that a single-dose regimen has benefits beyond safety and efficacy," Dr. Jorgensen added. "It can maximize patient compliance and thereby reduce the potential for the development of antibiotic resistance. Of course, Brilacidin's unique mechanism of action to penetrate the bacterial cell wall to eradicate bacteria is another reason why resistance is unlikely to develop. Further, Brilacidin has anti-inflammatory and anti-biofilm properties. When considering all these factors, Brilacidin has the potential to transform the way we treat infectious diseases."

In addition to the clinical data from the ABSSSI trial, Cellceutix will also present important preclinical data. The abstract entitled Synthetic Novel Host Defense Protein Mimetics for the Treatment of Gram-Negative Bacterial Infections has been accepted for oral presentation in the session entitled Drug Discovery. "This is an opportunity for experts to hear about the other promising defensin-mimetics -- not just Brilacidin," said Dr. Jorgensen. "These compounds have potential to treat serious Gram-negative infections, including those identified by CDC as 'antibiotic resistance threats.' "